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ABSTRACT 
The optimal treatment of schizophrenia poses a challenge to develop more effective treatments and safer drugs, to overcome poor 
compliance, discontinuation and frequent switching with available antipsychotics. Many antipsychotic medications are currently approved 
by FDA for the treatment of schizophrenia, but response to these agents remains highly variable. Iloperidone is a new dopamine type 
2/serotonin type 2A (D2/5-HT2A) antagonist structurally related to risperidone, expected to give better efficacy with less extrapyramidal 
symptoms than D2 receptor antagonist antipsychotics. Iloperidone is more efficacious in terms of cognitive functions, less problematic 
regarding weight gain and metabolic disturbances. 
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INTRODUCTION 
Schizophrenia is severely debilitating psychiatric 
disorder observed worldwide, causing recurring and 
progressive episodes of positive and negative symptoms, 
and disturbed cognitive function. The optimal treatment 
of schizophrenia poses a challenge to develop more 
effective treatments and safer drugs, to overcome poor 
compliance, discontinuation and frequent switching with 
available antipsychotics. Many antipsychotic 
medications are currently approved by FDA for the 
treatment of schizophrenia, but response to these agents 
remains highly variable. Atypical antipsychotics are 
considered as the choice of treatment of schizophrenia as 
they lack extrapyramidal side effects (EPSE) and lack of 
sustained prolactin elevation
1
. Considering all exposed, 
iloperidone has showed a good overall effectiveness 
profile despite dosing (12-24mg/day) against placebo 
and haloperidol 
2, 3
. 
Iloperidone newer 2
nd
 generation antipsychotic approved 
in 2009 found to be equally efficacious to haloperidol, 
risperidone and Olanzapine. Iloperidone is more 
efficacious in terms of cognitive functions, less 
problematic regarding weight gain and metabolic 
disturbances. Iloperidone is the 1
st
 antipsychotic with 
specific genetic markers. Six single nucleotide 
polymorphisms identified that correlate with iloperidone 
response 
4
. 
MECHANISM OF ACTION 
Iloperidone a piperinidyl benzisoxazole derivative 
structurally related to risperidone. Iloperidone is a novel 
2
nd
 generation antipsychotic and like risperidone, 
ziprasidone and other atypical antipsychotics, 
iloperidone has high affinity for 5HT2A, D2 and D3 
receptors and has moderate affinity for D4, 5HT6, 5HT7 
and alpha-1receptors.Iloperidone has low affinity for 
5HT1A, 5HT2C, D1, H1 receptors and has no 
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appreciable affinity for muscarinic M1-M5 receptors. 
Iloperidone’s receptor affinity profile regarding 5HT2 
and D2 resembles other 2
nd
 generation antipsychotics 
and would predict its efficacy as an antipsychotic in 
general, and lowered likelihood to be associated with 
extrapyramidal symptoms 
1, 5-8
. Affinity for the 
5HT1A/6 could potentially enhance cognition and 
5HT2C may enhance iloperidone’s efficacy in treating 
the negative symptoms and may also provide the 
anxiolytic effect. Affinity for 5HT6 could improve the 
cognitive function 
1, 6
. 
PHARMACOKINETICS 
Iloperidone is rapidly absorbed reaching peak 
concentration between 2 and 5 hours after oral 
administration with a bioavailability of 96% 
9-11
. Food 
did not alter the bioavailability. The plasma half-life of 
iloperidone varies between 5.4–7 hours and significantly 
delayed to 33.7 hours in patients with renal impairment 
12
. Plasma protein binding is 93%. Volume of 
distribution of the drug is large 
11
. Elimination of 
iloperidone is mainly through hepatic, metabolism to O-
desmethyl iloperidone and 2-hydroxyl iloperidone by 
CYP2D6 and CYP3A4. Subsequent changes of these 
metabolites occur via oxidation and conjugation with 
glucoronic acid. Biliary excretion appears to be the 
predominant elimination pathway, iloperidone is highly 
metabolized, <1% of the drug excreted unchanged 
1, 6
. 
Dose: 
Dose initiated with 1mg BD and maintenance dose is 
12mg/day (6mg BD). The maximum dose can be kept 
upto 24mg/day (12mg BD). The serum levels of 
iloperidone that corresponds with maximum therapeutic 
response were 5 -8 ng/ml 
1
. 
Adverse drug reactions: 
Safety data obtained from the pooled four week and six 
week, fixed dose or flexible dose phase 2 and 3 studies
13-
15
. The drug side effects like orthostatic hypotension, dry 
mouth, dyspepsia, weight gain, QTc prolongation, and 
somnolence have been reported during the trials.The 
side effects as dizziness, tachycardia and weight gain at 
least twice as common with higher doses (20-24mg/day) 
than with lower doses (10-16mg/day) 
9
. Insomnia and 
anxiety have been observed in long term studies 
comparing iloperidone with haloperidol 
14
. 
Drug interactions: 
The importance of CYP2D6 in iloperidone clearance is 
underlined by its interaction with potent inhibitors of 
this enzyme. A dosage reduction of the drug needed if 
administered with enzyme inhibitors as fluoxetine, 
erythromycin, azole antifungals and protease inhibitors, 
as the drug is metabolized by CYP3A4 and CYP2D6. 
Use in special circumstances 
9, 15-16
 
Safe use of iloperidone during pregnancy is not 
established. FDA leveled the drug as category C for 
pregnancy risk. Safety of the drug during lactation is 
also not established. 
Advantages:  
Prolactin levels are not significantly affected by the 
drug. Iloperidone is considered to be a prolactin sparing 
atypical antipsychotic, iloperidone induced hyper-
prolactinemia may rarely be encountered as a side effect 
in susceptible individuals 
17
. The favourable 
Extrapyramidal side effects (EPSE) and akathesia profile 
of iloperidone makes it an attractive choice for patients 
whose compliance is limited by these side effects 
18
. 
Switching to iloperidone from discontinuation of 
previous antipsychotics has revealed results in 
consistency with previous studies regarding favorable 
akathesia and EPSE profile 
19
. 
Flexible dosing of iloperidone for maintenance phase 
therapy with a modal dose of 12mg/day was effective in 
preventing relapse in subjects
20
. 
Use:  
As a broad spectrum antipsychotic with efficacy against 
positive &negative symptoms and particularly improves 
cognitive symptoms, makes it a promising agent in acute 
schizophrenia. It has excellent tolerability profile. 
SUMMARY 
Schizophrenia is a severely debilitating psychiatric 
disorder worldwide, with a median life time prevalence 
of 0.7-1%. Optimal treatment of the disease is still 
challenging to develop safe and effective antipsychotic 
drugs. Iloperidone is a novel 2
nd
 generation 
antipsychotic drug for the treatment of schizophrenia. As 
it has a low risk of causing the extrapyramidal symptoms 
and adverse metabolic effects. However many 
disadvantages like orthostatic hypotension, risk of QT 
prolongation must be kept in mind. To conclude it may 
be a very useful and safe option for the treatment of 
schizophrenia but it doesn’t necessarily possess any 
distinct advantage over other antipsychotic agents.
 
 
 
 
 
 
 
 
Dutta                                                                                                         Journal of Drug Delivery & Therapeutics. 2017; 7(3):8-10                                     
ISSN: 2250-1177                                                                  [10]                                                                  CODEN (USA): JDDTAO 
REFERENCES  
1. Lavie A, Michael A, Megan J. A novel atypical antipsychotic 
for the treatment of schizophrenia. Formulary 2008; 43:190-
203. 
2. Tonin FS, Wiens A, Llimos FF, Pontarolo R. Iloperidone in 
the treatment of schizophrenia- an evidence based review of 
its place in therapy. Core Evid 2016; 11:49-61. 
3. Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. 
Long term safety and tolerability of iloperidone: results from 
a 25week, open label extension trial. CNS Spectr. 
2013;18(1):43–54. 
4. Albers LJ, Musenga A, Raggi MA. Iloperidone: a new 
benzisoxazole atypical antipsychotic drug. Is it novel enough 
to impact the crowded atypical antipsychotic market? Expert 
Opin Investig Drugs 2008; 17:61-75. 
5. Kongsamut S, Roehr JE, Cai J, et al. Iloperidone binding to 
human and rat dopamine and 5-HT receptors. Eur J 
Pharmacol 1996; 317:417–23. 
6. Kalkman HO, Subramanian N, Hoyer D. Extended 
radioligand binding profile of iloperidone: A broad spectrum 
dopamine/serotonin/norepinephrine receptor antagonist for 
the management of psychotic disorders. Neuropsycho 
pharmacology 2001; 25:904–14. 
7. Richelson E, Souder T. Binding of antipsychotic drugs to 
human brain receptors: Focus on newer generation 
compounds. Life Sci. 2000; 68:29-39. 
8. Kalkman HO, Feuerbach D, Lotscher E, Schoeffter P. 
Functional characterization of the novel antipsychotic 
iloperidone at human D2, D3, alpha2C,5-HT6 , and 5-HT1A 
receptors. Life Sci. 2003; 73:1151–59. 
9. CacciaS, Pasina L, Nobili A. New atypical antipsychotics for 
schizophrenia: Iloperidone. Drug Des Devel Ther. 
2010:4:33-48. 
10. Subramaian N, Kalkman HO. Receptor profile of P88-8991 
and P95-12113, metabolites of the novel antipsychotic 
iloperidone. Prog Neuropsycho pharmacol Biol Psychiatry. 
2002;26 :553-60. 
11. Jain KK. An assessment of iloperidone for the treatment of 
schizophrenia. Expert Opin Investig Drugs. 2000; 
9(12):2935–43. 
12. Sainati SM, Hubbard JW, Chi E, Grasing K, Brecher MB. 
Safety, tolerability, and effect of food on the 
pharmacokinetics of iloperidone (HP 873), a potential 
atypical antipsychotic. J Clin Pharmacol. 1995; 35:713–20. 
13. Potkin SG, Litman RE, Torres R et al. Efficacy of 
iloperidone in the treatment of schizophrenia: initial phase 3 
studies. J Clin Psycho pharmacol. 2008; 28(suppl 1):S4-11. 
14. Cutler AJ, Kalali AH, Weiden PJ et al. Four week, double-
blind, placebo and ziprasidone controlled trial of iloperidone 
in patients with acute exacerbations of schizophrenia. J Clin 
Psycho pharmacol 2008; 28(suppl1):S20-8.  
15. Weiden PJ, Cutler AJ, Polymeropoulos MH et al. Safety 
profile of iloperidone: a pooled analysis of 6-week acute-
phase pivitol trials. J Clin Psycho pharmacol 2008; 28(suppl 
1):S12- 9. 
16. Kane JM, Lauriello J, Laska E et al. Long-term efficacy and 
safety of iloperidone: results from 3 clinical trials for the 
treatment of schizophrenia. J Clin Psychopharmacol 2008; 
28(suppl 1):S29-35. 
17. Dutta A, Baruna S, Dan A, Chakraborty K, Mandal M. 
Iloperidone-induced galactorrhea in middle aged female. 
Indian J Psychol Med.2012; 34(4):396-98. 
18. Dargani NV, Malhotra AK. Safety profile of iloperidone in 
the treatment of schizophrenia. Expert Opin Drug Saf 2014; 
13(2):241-46. 
19. Citrome L, Weiden PJ, Alva G, Glick ID, Jackson R, 
Mattingly G, Kianifard F et al. Switching to iloperidone: An 
omnibus of clinically relevant observations from a 12week, 
open label, randomized clinical trial in 500 persons with 
schizophrenia. Clin Schizo phr Relat Psychoses 2015; 
8(4):183-95. 
20. Weiden PJ, Manning R, Wolfgang CD, Ryan JM, 
MancioneL, HanG, Ahmed S, Mayo MG. Randomized trial 
of iloperidone for prevention of relapse in Schizophrenia: 
The REPRIEVE study.CNS Drugs 2016;30(8):735-47. 
                                                                      
 
